<DOC>
	<DOCNO>NCT00003072</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different combination may kill tumor cell . PURPOSE : Randomized phase II double-blinded trial study effectiveness paclitaxel carboplatin give either amifostine placebo patient metastatic stage III stage IV ovarian cancer metastatic stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Ovarian Cancer Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether patient metastatic ovarian non-small cell lung cancer receive carboplatin paclitaxel significantly few neuropathic event treat amifostine . OUTLINE : This randomize , parallel group , double blind , control study . Patients randomize either amifostine control group . All patient receive intravenous paclitaxel 3 hour , follow carboplatin every 3 week 6 cycle . Patients randomized amifostine group receive intravenous amifostine administer 15 minute infusion 30 minute prior paclitaxel therapy . Patients randomize control group receive intravenous placebo solution . Patients discontinue study disease progression unacceptable toxic effect 2 cycle treatment . Patients follow monthly 8 month post treatment . PROJECTED ACCRUAL : A total 80 patient accrue ( 40 advance ovarian cancer 40 advance non-small cell lung cancer ) within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III/IV ovarian nonsmall cell lung cancer PATIENT CHARACTERISTICS : Age : 18 Performance Status : ECOG 02 Life Expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 3.0 mg/dL Renal : Creatinine great 2 mg/dL Other : Not pregnant nursing No history platinum , paclitaxel amifostine hypersensitivity Prior myelosuppressive event allow No clinically significant ascites PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy within 1 month study Endocrine therapy : Not specify Radiotherapy : No prior radiation therapy within 1 month study Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III non-small cell lung cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>neurotoxicity</keyword>
</DOC>